Japan Drug Approvals | Healthcare

Japan Drug Approvals | 2023 | MHLW | PMDA | iPharmaCenter

Also read: Top pharma companies by revenues | 2023 Eisai and Biogen have jointly announced the approval of Leqembi intravenous infusion...

Levima received orphan designation from MHLW |Japan drug approvals | Japan Healthcare System

Mar 12. 2021 Takeda’s New Drug Application was submitted for MHLW in Japan for Hereditary Angioedema Attacks Takeda announced that it...

Lynparza was approved for three more indications in Japan

AstraZeneca and Merck announced that Lynparza (olaparib) was approved for three more indications in Japan. The three new cancer...

Merck’s Keytruda received one more indication and dosage form approval in Japan

Merck has announced that it has received the approval of its anti-PD-1 therapy, Keytruda (pembrolizumab) for radically unresectable,...

Gilead announced the positive Phase 3 trial of remdesivir in COVID-19 patients

Gilead has announced top-line Phase 3 trial results of remdesivir in patients with COVID-19. The drug is indicated in moderate COVID-19...

Astellas received approval for Xtandi in Japan for prostate cancer

Astellas announced that it had received approval from Japan Ministry of Health, Labour and Welfare (MHLW) for Xtandi (enzalutamide) for...

AstraZeneca's Lokelma approved in Japan

AstraZeneca has announced that it has received the approval for Lokelma (sodium zirconium cyclosilicate) in Japan. Japan's Ministry of...